Virtus Advisers LLC Has $47,000 Position in Puma Biotechnology, Inc. $PBYI

Virtus Advisers LLC trimmed its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 75.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,817 shares of the biopharmaceutical company’s stock after selling 41,614 shares during the period. Virtus Advisers LLC’s holdings in Puma Biotechnology were worth $47,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC increased its position in Puma Biotechnology by 214.1% in the 2nd quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 6,450 shares during the last quarter. Causeway Capital Management LLC bought a new stake in shares of Puma Biotechnology in the 1st quarter valued at approximately $42,000. Savant Capital LLC bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at approximately $44,000. Ethic Inc. acquired a new position in Puma Biotechnology in the second quarter worth approximately $51,000. Finally, D Orazio & Associates Inc. bought a new position in Puma Biotechnology during the second quarter valued at approximately $52,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Stock Down 1.8%

Shares of Puma Biotechnology stock opened at $4.96 on Tuesday. Puma Biotechnology, Inc. has a 12-month low of $2.58 and a 12-month high of $6.12. The company has a quick ratio of 1.62, a current ratio of 1.73 and a debt-to-equity ratio of 0.10. The stock has a 50 day moving average price of $5.11 and a two-hundred day moving average price of $4.33. The stock has a market capitalization of $249.94 million, a P/E ratio of 5.06 and a beta of 1.35.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12. The business had revenue of $54.48 million during the quarter, compared to analysts’ expectations of $51.00 million. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts expect that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings lowered shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Insiders Place Their Bets

In other Puma Biotechnology news, Director Michael Patrick Miller sold 20,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $4.86, for a total transaction of $97,200.00. Following the completion of the sale, the director directly owned 54,000 shares in the company, valued at $262,440. This represents a 27.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 23.30% of the stock is currently owned by corporate insiders.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.